Clinical Cancer Research Meeting Calendar AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shih, C.-H.
Right arrow Articles by Kitajima, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shih, C.-H.
Right arrow Articles by Kitajima, M.
Clinical Cancer Research Vol. 6, 1161-1168, March 2000
© 2000 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Vascular Endothelial Growth Factor Expression Predicts Outcome and Lymph Node Metastasis in Squamous Cell Carcinoma of the Esophagus1

Chih-Horng Shih, Soji Ozawa, Nobutoshi Ando, Masakazu Ueda2 and Masaki Kitajima

Department of Surgery, School of Medicine, Keio University, Shinjuku-ku, Tokyo 160-8582, Japan

Vascular endothelial growth factor (VEGF) expression and tumor microvessel density (MVD) were examined by immunohistochemical staining in 117 cases of thoracic esophageal squamous cell carcinoma. Thirty-six (31%) of the 117 cases were evaluated as VEGF-positive. The average number of metastatic lymph nodes at surgery was 5.6 in the VEGF-positive cases and 3.0 in the VEGF-negative cases and was significantly higher in those with VEGF-positive cases (P = 0.04). The incidence of pathological tumor (pT)2–4 cases among the high-MVD cases was significantly higher than among the low-MVD cases (P = 0.01). MVD was 59.4 ± 4.7 (mean ± SE)/mm2 in the VEGF-positive cases and 47.9 ± 3.8/mm2 in the VEGF-negative cases. The MVD of the VEGF-positive tumors was higher than that of VEGF-negative tumors, but the difference was not significant (P = 0.08). The survival rate of the patients with high-MVD tumors was significantly poorer than those with low-MVD tumors, and the survival rate of those patients with VEGF-positive tumors was significantly poorer than in those with VEGF-negative tumors (P = 0.009 and P = 0.04, respectively). The cumulative survival rates in the VEGF-positive groups were found to be significantly poorer in the pT3 and pathological node (pN)1 groups when stratified according to pT factor (pathological T category) and pN factor (pathological N category) in the tumor-node-metastasis (TNM) classification. VEGF expression had the second highest hazard ratio in the multivariate analysis, after pN factor. These results indicate that VEGF is a useful marker for predicting the outcome in patients with more advanced esophageal squamous cell carcinoma. It seems that TNM factors and VEGF expression are important factors in the selection of appropriate treatments.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
Y. Hiyoshi, H. Kamohara, R. Karashima, N. Sato, Y. Imamura, Y. Nagai, N. Yoshida, E. Toyama, N. Hayashi, M. Watanabe, et al.
MicroRNA-21 Regulates the Proliferation and Invasion in Esophageal Squamous Cell Carcinoma
Clin. Cancer Res., March 15, 2009; 15(6): 1915 - 1922.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Guo, Z. Chen, L. Zhang, F. Zhou, S. Shi, X. Feng, B. Li, X. Meng, X. Ma, M. Luo, et al.
Distinctive MicroRNA Profiles Relating to Patient Survival in Esophageal Squamous Cell Carcinoma
Cancer Res., January 1, 2008; 68(1): 26 - 33.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Ekman, M. Bergqvist, C.-H. Heldin, and J. Lennartsson
Activation of Growth Factor Receptors in Esophageal Cancer Implications for Therapy
Oncologist, October 1, 2007; 12(10): 1165 - 1177.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
T. Kii, H. Takiuchi, S. Kawabe, M. Gotoh, S. Ohta, T. Tanaka, S. Kuwakado, H. Nishitani, and K.-i. Katsu
Evaluation of Prognostic Factors of Esophageal Squamous Cell Carcinoma (Stage II III) After Concurrent Chemoradiotherapy Using Biopsy Specimens
Jpn. J. Clin. Oncol., August 20, 2007; (2007) hym077v1.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
N. Boku, A. Ohtsu, F. Nagashima, K. Shirao, and W. Koizumi
Relationship between Expression of Vascular Endothelial Growth Factor in Tumor Tissue from Gastric Cancers and Chemotherapy Effects: Comparison between S-1 alone and the Combination of S-1 plus CDDP
Jpn. J. Clin. Oncol., August 2, 2007; (2007) hym057v1.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
N. Boku, A. Ohtsu, S. Yoshida, K. Shirao, Y. Shimada, I. Hyodo, H. Saito, Y. Miyata, and Gastrointestinal Oncology Study Group of Japan Cli
Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin
Jpn. J. Clin. Oncol., May 23, 2007; (2007) hym015v1.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Chen, M. E. Rose, H. Hwang, R. G. Nines, and G. D. Stoner
Black raspberries inhibit N-nitrosomethylbenzylamine (NMBA)-induced angiogenesis in rat esophagus parallel to the suppression of COX-2 and iNOS
Carcinogenesis, November 1, 2006; 27(11): 2301 - 2307.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
J. Y. Choi, K.-T. Jang, Y. M. Shim, K. Kim, G. Ahn, K.-H. Lee, Y. Choi, Y. S. Choe, and B.-T. Kim
Prognostic Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Esophageal Squamous Cell Carcinoma: Comparison With Positron Emission Tomography
Ann. Surg. Oncol., August 1, 2006; 13(8): 1054 - 1062.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
W. P. Tew, D. P. Kelsen, and D. H. Ilson
Targeted Therapies for Esophageal Cancer
Oncologist, September 1, 2005; 10(8): 590 - 601.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
M. H. Kulke, R. D. Odze, J. D. Mueller, H. Wang, M. Redston, and M. M. Bertagnolli
Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer
J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1579 - 1586.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol., November 1, 2002; 20(21): 4368 - 4380.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
L. Hlatky, P. Hahnfeldt, and J. Folkman
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
J Natl Cancer Inst, June 19, 2002; 94(12): 883 - 893.
[Full Text] [PDF]


Home page
JCOHome page
B. C. Kuenen, L. Rosen, E. F. Smit, M. R.N. Parson, M. Levi, R. Ruijter, H. Huisman, M. A. Kedde, P. Noordhuis, W. J.F. van der Vijgh, et al.
Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors
J. Clin. Oncol., March 15, 2002; 20(6): 1657 - 1667.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Hironaka, T. Hasebe, T. Kamijo, A. Ohtsu, N. Boku, S. Yoshida, H. Saitoh, and A. Ochiai
Biopsy Specimen Microvessel Density Is a Useful Prognostic Marker in Patients with T2-4M0 Esophageal Cancer Treated with Chemoradiotherapy
Clin. Cancer Res., January 1, 2002; 8(1): 124 - 130.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold
Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival
J. Clin. Oncol., January 15, 2001; 19(2): 577 - 583.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.